Syngene International Limited
Get $10 bonus on your first $100 deposit for SYNGENE.NS
Get $10 bonus on your first $100 deposit for SYNGENE.NS
Syngene International Limited (SYNGENE.NS) Stock Competitors & Peer Comparison
See (SYNGENE.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SYNGENE.NS | ₹391.10 | -1.34% | 157.1B | 44.85 | ₹8.72 | +0.32% |
| BIOCON.BO | ₹352.55 | -3.45% | 447.4B | 72.39 | ₹4.87 | +0.14% |
| BIOCON.NS | ₹352.55 | -3.46% | 447.4B | 72.39 | ₹4.87 | +0.14% |
| ANTHEM.NS | ₹660.75 | -0.74% | 371.2B | 76.92 | ₹8.59 | N/A |
| PPLPHARMA.NS | ₹142.18 | -0.23% | 188.2B | -114.66 | -₹1.24 | +0.10% |
| ONESOURCE.NS | ₹1,404.50 | -2.22% | 161B | 793.50 | ₹1.77 | N/A |
| SYNGENE.BO | ₹390.95 | -1.36% | 157.1B | 44.63 | ₹8.76 | +0.32% |
| CONCORDBIO.BO | ₹1,025.95 | +0.52% | 107.3B | 34.49 | ₹29.75 | +1.04% |
| CONCORDBIO.NS | ₹1,025.10 | +0.50% | 107.2B | 34.48 | ₹29.73 | +1.04% |
| JUBLINGREA.NS | ₹579.15 | +1.07% | 91.5B | 34.58 | ₹16.75 | +0.95% |
Stock Comparison
SYNGENE.NS vs BIOCON.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, BIOCON.BO has a market cap of 447.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while BIOCON.BO trades at ₹352.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas BIOCON.BO's P/E ratio is 72.39. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BIOCON.BO's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is less volatile compared to BIOCON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check BIOCON.BO's competition here
SYNGENE.NS vs BIOCON.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, BIOCON.NS has a market cap of 447.4B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while BIOCON.NS trades at ₹352.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas BIOCON.NS's P/E ratio is 72.39. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BIOCON.NS's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is less volatile compared to BIOCON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check BIOCON.NS's competition here
SYNGENE.NS vs ANTHEM.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, ANTHEM.NS has a market cap of 371.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while ANTHEM.NS trades at ₹660.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas ANTHEM.NS's P/E ratio is 76.92. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ANTHEM.NS's ROE of +0.19%. Regarding short-term risk, SYNGENE.NS is more volatile compared to ANTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check ANTHEM.NS's competition here
SYNGENE.NS vs PPLPHARMA.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, PPLPHARMA.NS has a market cap of 188.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while PPLPHARMA.NS trades at ₹142.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas PPLPHARMA.NS's P/E ratio is -114.66. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to PPLPHARMA.NS's ROE of -0.02%. Regarding short-term risk, SYNGENE.NS is less volatile compared to PPLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check PPLPHARMA.NS's competition here
SYNGENE.NS vs ONESOURCE.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, ONESOURCE.NS has a market cap of 161B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while ONESOURCE.NS trades at ₹1,404.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas ONESOURCE.NS's P/E ratio is 793.50. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ONESOURCE.NS's ROE of +0.00%. Regarding short-term risk, SYNGENE.NS is less volatile compared to ONESOURCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check ONESOURCE.NS's competition here
SYNGENE.NS vs SYNGENE.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, SYNGENE.BO has a market cap of 157.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while SYNGENE.BO trades at ₹390.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas SYNGENE.BO's P/E ratio is 44.63. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SYNGENE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SYNGENE.BO's competition here
SYNGENE.NS vs CONCORDBIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, CONCORDBIO.BO has a market cap of 107.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while CONCORDBIO.BO trades at ₹1,025.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas CONCORDBIO.BO's P/E ratio is 34.49. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to CONCORDBIO.BO's ROE of +0.18%. Regarding short-term risk, SYNGENE.NS is less volatile compared to CONCORDBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check CONCORDBIO.BO's competition here
SYNGENE.NS vs CONCORDBIO.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, CONCORDBIO.NS has a market cap of 107.2B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while CONCORDBIO.NS trades at ₹1,025.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas CONCORDBIO.NS's P/E ratio is 34.48. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to CONCORDBIO.NS's ROE of +0.18%. Regarding short-term risk, SYNGENE.NS is less volatile compared to CONCORDBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check CONCORDBIO.NS's competition here
SYNGENE.NS vs JUBLINGREA.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, JUBLINGREA.NS has a market cap of 91.5B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while JUBLINGREA.NS trades at ₹579.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas JUBLINGREA.NS's P/E ratio is 34.58. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to JUBLINGREA.NS's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is less volatile compared to JUBLINGREA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check JUBLINGREA.NS's competition here
SYNGENE.NS vs BLUEJET.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, BLUEJET.NS has a market cap of 62B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while BLUEJET.NS trades at ₹357.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas BLUEJET.NS's P/E ratio is 21.12. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BLUEJET.NS's ROE of +0.26%. Regarding short-term risk, SYNGENE.NS is less volatile compared to BLUEJET.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check BLUEJET.NS's competition here
SYNGENE.NS vs BLUEJET.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, BLUEJET.BO has a market cap of 61.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while BLUEJET.BO trades at ₹356.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas BLUEJET.BO's P/E ratio is 21.09. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to BLUEJET.BO's ROE of +0.26%. Regarding short-term risk, SYNGENE.NS is less volatile compared to BLUEJET.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check BLUEJET.BO's competition here
SYNGENE.NS vs SUPRIYA.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, SUPRIYA.NS has a market cap of 49.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while SUPRIYA.NS trades at ₹612.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas SUPRIYA.NS's P/E ratio is 26.59. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SUPRIYA.NS's ROE of +0.19%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SUPRIYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SUPRIYA.NS's competition here
SYNGENE.NS vs SUPRIYA.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, SUPRIYA.BO has a market cap of 49.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while SUPRIYA.BO trades at ₹612.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas SUPRIYA.BO's P/E ratio is 26.60. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SUPRIYA.BO's ROE of +0.19%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SUPRIYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SUPRIYA.BO's competition here
SYNGENE.NS vs ZOTA.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, ZOTA.NS has a market cap of 33.7B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while ZOTA.NS trades at ₹1,110.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas ZOTA.NS's P/E ratio is -46.27. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ZOTA.NS's ROE of -0.31%. Regarding short-term risk, SYNGENE.NS is less volatile compared to ZOTA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check ZOTA.NS's competition here
SYNGENE.NS vs DCAL.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, DCAL.NS has a market cap of 23.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while DCAL.NS trades at ₹147.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas DCAL.NS's P/E ratio is 19.46. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is less volatile compared to DCAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check DCAL.NS's competition here
SYNGENE.NS vs DCAL.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, DCAL.BO has a market cap of 23.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while DCAL.BO trades at ₹147.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas DCAL.BO's P/E ratio is 19.45. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, SYNGENE.NS is less volatile compared to DCAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check DCAL.BO's competition here
SYNGENE.NS vs TITANBIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, TITANBIO.BO has a market cap of 20.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while TITANBIO.BO trades at ₹504.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas TITANBIO.BO's P/E ratio is 76.48. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, SYNGENE.NS is less volatile compared to TITANBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check TITANBIO.BO's competition here
SYNGENE.NS vs PANACEABIO.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, PANACEABIO.NS has a market cap of 19.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while PANACEABIO.NS trades at ₹323.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas PANACEABIO.NS's P/E ratio is -254.65. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is less volatile compared to PANACEABIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check PANACEABIO.NS's competition here
SYNGENE.NS vs PANACEABIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, PANACEABIO.BO has a market cap of 19.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while PANACEABIO.BO trades at ₹322.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas PANACEABIO.BO's P/E ratio is -254.25. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is more volatile compared to PANACEABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check PANACEABIO.BO's competition here
SYNGENE.NS vs 3BBLACKBIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, 3BBLACKBIO.BO has a market cap of 10.5B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while 3BBLACKBIO.BO trades at ₹1,228.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas 3BBLACKBIO.BO's P/E ratio is 18.49. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to 3BBLACKBIO.BO's ROE of N/A. Regarding short-term risk, SYNGENE.NS is less volatile compared to 3BBLACKBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check 3BBLACKBIO.BO's competition here
SYNGENE.NS vs FERMENTA.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, FERMENTA.BO has a market cap of 9.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while FERMENTA.BO trades at ₹337.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas FERMENTA.BO's P/E ratio is 11.39. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to FERMENTA.BO's ROE of +0.25%. Regarding short-term risk, SYNGENE.NS is less volatile compared to FERMENTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check FERMENTA.BO's competition here
SYNGENE.NS vs KILPEST.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, SYNGENE.NS is more volatile compared to KILPEST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check KILPEST.BO's competition here
SYNGENE.NS vs TAKE.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, TAKE.BO has a market cap of 6.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while TAKE.BO trades at ₹41.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas TAKE.BO's P/E ratio is -412.20. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TAKE.BO's ROE of +0.12%. Regarding short-term risk, SYNGENE.NS is more volatile compared to TAKE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check TAKE.BO's competition here
SYNGENE.NS vs TAKE.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, TAKE.NS has a market cap of 6.1B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while TAKE.NS trades at ₹41.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas TAKE.NS's P/E ratio is -412.10. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TAKE.NS's ROE of +0.12%. Regarding short-term risk, SYNGENE.NS is more volatile compared to TAKE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check TAKE.NS's competition here
SYNGENE.NS vs SMSLIFE.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, SMSLIFE.BO has a market cap of 3.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while SMSLIFE.BO trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas SMSLIFE.BO's P/E ratio is 21.00. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SMSLIFE.BO's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SMSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SMSLIFE.BO's competition here
SYNGENE.NS vs HALEOSLABS.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, HALEOSLABS.BO has a market cap of 3.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while HALEOSLABS.BO trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas HALEOSLABS.BO's P/E ratio is 19.80. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is more volatile compared to HALEOSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check HALEOSLABS.BO's competition here
SYNGENE.NS vs HALEOSLABS.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, HALEOSLABS.NS has a market cap of 3.9B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while HALEOSLABS.NS trades at ₹1,287.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas HALEOSLABS.NS's P/E ratio is 19.60. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, SYNGENE.NS is less volatile compared to HALEOSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check HALEOSLABS.NS's competition here
SYNGENE.NS vs SMSLIFE.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, SMSLIFE.NS has a market cap of 3.8B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while SMSLIFE.NS trades at ₹1,245.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas SMSLIFE.NS's P/E ratio is 20.15. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SMSLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SMSLIFE.NS's competition here
SYNGENE.NS vs LYKALABS.NS Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, LYKALABS.NS has a market cap of 2B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while LYKALABS.NS trades at ₹55.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas LYKALABS.NS's P/E ratio is -326.65. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to LYKALABS.NS's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check LYKALABS.NS's competition here
SYNGENE.NS vs LYKALABS.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, LYKALABS.BO has a market cap of 2B. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while LYKALABS.BO trades at ₹55.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas LYKALABS.BO's P/E ratio is 93.31. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to LYKALABS.BO's ROE of -0.01%. Regarding short-term risk, SYNGENE.NS is less volatile compared to LYKALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check LYKALABS.BO's competition here
SYNGENE.NS vs ALFAVIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, ALFAVIO.BO has a market cap of 428.8M. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while ALFAVIO.BO trades at ₹13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas ALFAVIO.BO's P/E ratio is -453.33. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to ALFAVIO.BO's ROE of -0.00%. Regarding short-term risk, SYNGENE.NS is more volatile compared to ALFAVIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check ALFAVIO.BO's competition here
SYNGENE.NS vs SAMSRITA.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, SAMSRITA.BO has a market cap of 232.1M. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while SAMSRITA.BO trades at ₹15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas SAMSRITA.BO's P/E ratio is -3.93. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SAMSRITA.BO's ROE of -0.61%. Regarding short-term risk, SYNGENE.NS is more volatile compared to SAMSRITA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check SAMSRITA.BO's competition here
SYNGENE.NS vs STARSOURCE.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, STARSOURCE.BO has a market cap of 173.9M. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while STARSOURCE.BO trades at ₹115.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas STARSOURCE.BO's P/E ratio is -1.43. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, SYNGENE.NS is less volatile compared to STARSOURCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check STARSOURCE.BO's competition here
SYNGENE.NS vs TRABI.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, TRABI.BO has a market cap of 159.9M. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while TRABI.BO trades at ₹2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas TRABI.BO's P/E ratio is -8.79. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to TRABI.BO's ROE of -0.19%. Regarding short-term risk, SYNGENE.NS is less volatile compared to TRABI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check TRABI.BO's competition here
SYNGENE.NS vs VANTABIO.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, VANTABIO.BO has a market cap of 107.7M. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while VANTABIO.BO trades at ₹15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas VANTABIO.BO's P/E ratio is -2.21. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to VANTABIO.BO's ROE of -0.49%. Regarding short-term risk, SYNGENE.NS is more volatile compared to VANTABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SYNGENE.NS.Check VANTABIO.BO's competition here
SYNGENE.NS vs GVBL.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, GVBL.BO has a market cap of 73.3M. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while GVBL.BO trades at ₹24.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas GVBL.BO's P/E ratio is -218.27. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to GVBL.BO's ROE of +0.03%. Regarding short-term risk, SYNGENE.NS is less volatile compared to GVBL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check GVBL.BO's competition here
SYNGENE.NS vs SERVOTEACH.BO Comparison April 2026
SYNGENE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYNGENE.NS stands at 157.1B. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, SYNGENE.NS is priced at ₹391.10, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYNGENE.NS currently has a P/E ratio of 44.85, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, SYNGENE.NS's ROE is +0.07%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, SYNGENE.NS is less volatile compared to SERVOTEACH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SYNGENE.NS.Check SERVOTEACH.BO's competition here